Dapivirine + Pritelivir + Levonorgestrel 3D Printed Intravaginal Ring
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Vaginal Ring
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): University of North Carolina
Details
- API: Dapivirine, Pritelivir, Levonorgestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Endometrial Changes
- Cervical Mucus Changes
- Inhibition of Sperm Motility
- Ovulation Inhibition
- Anti-Microbial
- Inactive Materials: Silicone-Urethane-Based Resin
- Regimen: Not Yet Determined
- MPT: Potential MPT
- Promising Attributes: The method is intended to offer pregnancy prevention, HIV prevention, and prevention of herpes simplex virus. The novel 3D printing process could lead to more rapid, scalable, and cost-effective manufacturing.
Product Status
Active Pre-Clinical Research
History
2020: A novel approach to intravaginal ring design and manufacturing is published by the Benhabbour Research Laboratory.
2024: Publication reports stability and safety of the first 3D printed multipurpose prevention technology (MPT) intravaginal ring for prevention of HIV (with DPV), HSV-2 (with PTV), and unintended pregnancy (with LNG).
2025: Publication reports favorable release rates following initial burst for triple-API rings tested in vitro, though note that accelerated stability studies suggest degradation of PTV and LNG while in storage. Placebo rings were well-tolerated in mice.